<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>To clarify the role of <z:chebi fb="0" ids="26995">thromboxane</z:chebi> (TX) A2 in arterial <z:e sem="disease" ids="C0302148,C0087086" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">thrombus</z:e> formation, we examined the antithrombotic effects of both a <z:chebi fb="0" ids="15627">TXA2</z:chebi> synthetase inhibitor (CV-4151) and a <z:chebi fb="0" ids="15627">TXA2</z:chebi> receptor <z:chebi fb="68" ids="48706">antagonist</z:chebi> (AA-2414) on the rabbit common carotid artery <z:mp ids='MP_0005048'>thrombosis</z:mp> which was induced by injury of the endothelium by treatment with 0.25% pronase solution </plain></SENT>
<SENT sid="1" pm="."><plain>CV-4151 (1,10 mg/kg, p.o.) and AA-2414 (10 mg/kg, p.o.) significantly inhibited <z:e sem="disease" ids="C0302148,C0087086" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">thrombus</z:e> formation </plain></SENT>
<SENT sid="2" pm="."><plain>Furthermore, the combined use of CV-4151 and AA-2414 (0.1 mg/kg, p.o </plain></SENT>
<SENT sid="3" pm="."><plain>each) significantly inhibited <z:e sem="disease" ids="C0302148,C0087086" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">thrombus</z:e> formation, though these drugs at the same doses had no effect when administered singly </plain></SENT>
<SENT sid="4" pm="."><plain>The plasma level of <z:chebi fb="0" ids="28667">11-dehydro TXB2</z:chebi> increased significantly during <z:e sem="disease" ids="C0302148,C0087086" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">thrombus</z:e> formation, and CV-4151 (10 mg/kg) markedly inhibited this increase </plain></SENT>
<SENT sid="5" pm="."><plain>There was a significant correlation between the in vivo antithrombotic effects of these drugs and their ex vivo inhibitory effects on <z:chebi fb="0" ids="15843">arachidonic acid</z:chebi>-induced platelet aggregation </plain></SENT>
<SENT sid="6" pm="."><plain>The antithrombotic effect of CV-4151 also correlated significantly with its ability to inhibit the production of serum <z:chebi fb="0" ids="15627">TXA2</z:chebi> </plain></SENT>
<SENT sid="7" pm="."><plain>These results show that <z:chebi fb="0" ids="15627">TXA2</z:chebi> may play an important role in the <z:e sem="disease" ids="C0302148,C0087086" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">thrombus</z:e> formation in <z:hpo ids='HP_0004420'>arterial thrombosis</z:hpo> </plain></SENT>
</text></document>